297 related articles for article (PubMed ID: 31670006)
21. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
22. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830
[TBL] [Abstract][Full Text] [Related]
23. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
24. Update on raltegravir and the development of new integrase strand transfer inhibitors.
Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
[TBL] [Abstract][Full Text] [Related]
25. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
Raffi F; Wainberg MA
Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
[TBL] [Abstract][Full Text] [Related]
26. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A;
J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993
[TBL] [Abstract][Full Text] [Related]
27. Comparable
Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
[TBL] [Abstract][Full Text] [Related]
28. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
[TBL] [Abstract][Full Text] [Related]
29. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
30. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
31. Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
Mbhele N; Chimukangara B; Gordon M
Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
[TBL] [Abstract][Full Text] [Related]
33. Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV.
O'Halloran JA; Sahrmann J; Butler AM; Olsen MA; Powderly WG
J Acquir Immune Defic Syndr; 2020 Aug; 84(4):396-399. PubMed ID: 32243280
[TBL] [Abstract][Full Text] [Related]
34. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299
[TBL] [Abstract][Full Text] [Related]
35. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
Veil R; Poizot-Martin I; Reynes J; Goujard C; Seng R; Delobel P; Cotte L; Duvivier C; Rey D; Tran L; Surgers L; Allavena C; Lascoux Combe C; Cheret A; Meyer L
AIDS; 2020 Mar; 34(4):493-500. PubMed ID: 31764069
[TBL] [Abstract][Full Text] [Related]
36. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
[TBL] [Abstract][Full Text] [Related]
37. HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study.
Murrell DE; Cluck DB; Moorman JP; Brown SD; Wang KS; Duffourc MM; Harirforoosh S
Clin Drug Investig; 2019 Mar; 39(3):285-299. PubMed ID: 30623371
[TBL] [Abstract][Full Text] [Related]
38. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
39. Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
Hachiya A; Kirby KA; Ido Y; Shigemi U; Matsuda M; Okazaki R; Imamura J; Sarafianos SG; Yokomaku Y; Iwatani Y
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533248
[TBL] [Abstract][Full Text] [Related]
40. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
